Explore our current clinical trials for cardiology:
[Updated: 12/06/22]
Cardiovascular Surgery
Status:
In follow-up
Summary:
A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
Description:
A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban.
Electrophysiology
Status:
Active, in follow-up
Description:
The AMPLATZER™ Amulet™ Left Atrial Appendage (LAA) Occluder Trial is designed to evaluate the safety and effectiveness of the Amulet device compared to the approved WATCHMAN LAA closure device in patients with non-valvular atrial fibrillation and at a high risk for bleeding. Eligible patients will be randomized to receive either the Amulet device or the WATCHMAN device.
General Cardiology
Status:
Active, In follow-up
Summary:
A Cross-Sectional Study of Lipoprotein(a) Levels in Patients with Documented History of Atherosclerotic Cardiovascular Disease
Description:
This is a pre-screening cardiovascular outcome trial of patients with elevated Lipoprotein(a).
Status:
Enrolling
Summary:
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial
Description:
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Status:
Enrolling
Summary:
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Description:
This study is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Heart Failure
Status:
Active, in follow-up
Summary:
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Description:
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Vutrisiran in patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy).
Status:
Enrolling
Summary:
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68
Description:
This is a multicenter, randomized, double‐blind, parallel group, placebo‐controlled trial to evaluate the effect of in‐hospital initiation of Dapagliflozin on clinical outcomes in patients with Heart Failure with reduced Ejection Fraction who have been stabilized during hospitalization for acute Heart Failure.
Status:
Enrolling
Summary:
Study to Evaluate Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System
Description:
The primary objective of this study is to collect physiological measurement data and heart failure event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.
Status:
Active, in follow-up
Summary:
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events
Description:
The overarching goal of this prospective, multicenter study is to utilize data from the Bodyport scale to develop an index that allows for the early detection of worsening heart failure (HF). The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient’s home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
Status
Active, in follow-up
Summary
Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF)
Description
This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. The study device, the V-Wave Interartrial Shunt System, includes a permanent implant – the Shunt. The Shunt is placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. By transferring blood from the left to the right atrium, the Shunt is intended to reduce excessive left-sided cardiac filling pressures in patients with advanced Heart Failure.
Status
Enrolling
Summary
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Description
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction > 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 825 in Part B.
Interventional Cardiology
Status:
Active, in follow-up
Summary:
Study to Investigate the Efficacy & Safety of CSL112 in Subjects With Acute Coronary Syndrome
Description:
CSL112 is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in acute coronary syndrome (ACS) patients diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation.
Status:
Enrolling
Summary:
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement (COMPLETE TAVR)
Description:
This is a randomized, comparative effectiveness study of staged complete revascularization with Percutaneous Coronary Intervention (PCI) to treat Coronary Artery Disease vs medical management alone in patients with symptomatic aortic valve stenosis undergoing elective transfemoral Transcatheter Aortic Valve Replacement (TAVR).
Status:
Enrolling
Summary:
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts
Description:
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
Status:
Enrolling
Summary:
Surveillance Registry for Medtronic Coronary Post-Surveillance
Description:
A registry for the collection of data on coronary percutaneous interventions to help fulfill the new European Medical Devices Regulation requirements.
Status:
Active, in follow-up
Description:
The proposed registry will utilize retrospective and prospective observational methods to assess and compare the characteristics, treatment, and follow-up of confirmed or suspected COVID-19 adult (age ≥ 18 years old) patients presenting with ST segment elevation.
Status:
Active, in follow-up
Summary:
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (DCB)
Description:
This study is to demonstrate the safety & efficacy of the SurVeil DCB for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.
Status:
Enrolling
Description:
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post approval setting.
Status:
Enrolling
Summary:
Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
Description:
This multi-center, prospective, randomized controlled study compares PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system.
Status:
Enrolling
Description:
Study OPL-0301 is a Phase 2 proof-of-concept study to assess efficacy and safety of OPL-0301 in patients with post-myocardial infarction left ventricular dysfunction. Results from the study will contribute to a better understanding of the benefit-risk relationship for OPL-0301 in this population and inform the design of future pivotal studies.
Status:
Enrolling
Summary:
Impact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (IMPROVE)
Description:
This is a prospective, single-blind clinical investigation randomizing subjects to intravascular ultrasound (IVUS)-guided coronary stent implantation vs. angiography-guided coronary stent implantation in a 1:1 ratio.